Edmund K. Waller
Experienced in Hemolytic Anemia

Dr. Edmund K. Waller

Hematology Oncology
Emory Winship Cancer Institute
1365 Clifton Road Northeast, BldgC, 
Atlanta, GA 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
40 Years of Experience
Experienced in Hemolytic Anemia
Emory Winship Cancer Institute
1365 Clifton Road Northeast, BldgC, 
Atlanta, GA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Edmund Waller is a Hematologist Oncology provider in Atlanta, Georgia. Dr. Waller has been practicing medicine for over 40 years and is rated as an Experienced provider by MediFind in the treatment of Hemolytic Anemia. His top areas of expertise are Graft Versus Host Disease (GvHD), Chronic Graft Versus Host Disease (cGvHD), Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), and Bone Marrow Transplant.

His clinical research consists of co-authoring 286 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 6 articles and participated in 1 clinical trial in the study of Hemolytic Anemia.

Graduate Institution
Cornell Univ Medical College, 1985
Residency
Stanford University Hospital
Specialties
Hematology Oncology
Licenses
Internal Medicine in GA
Board Certifications
American Board Of Internal Medicine, 1991
Fellowships
Stanford University Hospital
Hospital Affiliations
Emory University Hospital Midtown
Emory University Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

Emory Winship Cancer Institute
1365 Clifton Road Northeast, BldgC, Atlanta, GA 30322

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
Enrollment Status: Recruiting
Publish Date: April 17, 2025
Intervention Type: Drug
Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Diffuse Large B Cell Lymphoma (DEEP T CELLS)
Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Diffuse Large B Cell Lymphoma (DEEP T CELLS)
Enrollment Status: Completed
Publish Date: January 20, 2025
Intervention Type: Drug, Biological
Study Drugs: Duvelisib, Tisagenlecleucel
Study Phase: Early Phase 1
A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 1703; Progress III); Companion Study: Microbiome and Immune Reconstitution in Cellular Therapies and Hematopoietic Stem Cell Transplantation (BMT CTN 1801; Mi-Immune)
A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 1703; Progress III); Companion Study: Microbiome and Immune Reconstitution in Cellular Therapies and Hematopoietic Stem Cell Transplantation (BMT CTN 1801; Mi-Immune)
Enrollment Status: Completed
Publish Date: April 04, 2024
Intervention Type: Drug, Procedure
Study Drugs: Tacrolimus, Methotrexate, Mycophenolate Mofetil, Cyclophosphamide
Study Phase: Phase 3
Itacitinib Monotherapy for Low Risk Graft-vs-Host Disease
Itacitinib Monotherapy for Low Risk Graft-vs-Host Disease
Enrollment Status: Completed
Publish Date: February 06, 2023
Intervention Type: Drug
Study Drug: Itacitinib
Study Phase: Phase 2
A Phase I Study of Neihulizumab (ALTB-168) in Patients With Steroid-refractory Acute Graft-versus-host Disease (SR-aGVHD) or Treatment-refractory Acute Graft-versus-host Disease (TR-aGVHD)
A Phase I Study of Neihulizumab (ALTB-168) in Patients With Steroid-refractory Acute Graft-versus-host Disease (SR-aGVHD) or Treatment-refractory Acute Graft-versus-host Disease (TR-aGVHD)
Enrollment Status: Completed
Publish Date: January 19, 2023
Intervention Type: Biological
Study Drug: Neihulizumab (AbGn-168H)
Study Phase: Phase 1
Phase II Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease
Phase II Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease
Enrollment Status: Completed
Publish Date: October 21, 2022
Intervention Type: Drug
Study Drugs: Natalizumab, Steroids
Study Phase: Phase 2
Phase Ib Study of Tisagenlecleucel in Combination With Pembrolizumab in Relapsed/Refractory (r/r) Diffuse Large B-cell Lymphoma (DLBCL) Patients.
Phase Ib Study of Tisagenlecleucel in Combination With Pembrolizumab in Relapsed/Refractory (r/r) Diffuse Large B-cell Lymphoma (DLBCL) Patients.
Enrollment Status: Completed
Publish Date: August 15, 2022
Intervention Type: Drug, Biological
Study Drugs: Tisagenlecleucel, Pembrolizumab
Study Phase: Phase 1
A Phase III, Multicenter, Randomized Controlled Study to Compare Safety and Efficacy of a Haploidentical HSCT and Adjunctive Treatment With ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted ex Vivo of Host Alloreactive T-cells, Versus a Haploidentical HSCT With Post-transplant Cyclophosphamide in Patients With a Hematologic Malignancy
A Phase III, Multicenter, Randomized Controlled Study to Compare Safety and Efficacy of a Haploidentical HSCT and Adjunctive Treatment With ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted ex Vivo of Host Alloreactive T-cells, Versus a Haploidentical HSCT With Post-transplant Cyclophosphamide in Patients With a Hematologic Malignancy
Enrollment Status: Terminated
Publish Date: May 24, 2022
Intervention Type: Drug, Biological, Procedure
Study Drugs: ATIR101 Ex Vivo-Depleted T Lymphocyte-Enriched Leukocyte, Cyclophosphamide
Study Phase: Phase 3
A Phase I Study of Mesenchymal Stromal Cells to Promote Stem Cell Engraftment in Patients With Severe Sickle Cell Disease Undergoing Haploidentical Hematopoietic Cell Transplantation
A Phase I Study of Mesenchymal Stromal Cells to Promote Stem Cell Engraftment in Patients With Severe Sickle Cell Disease Undergoing Haploidentical Hematopoietic Cell Transplantation
Enrollment Status: Withdrawn
Publish Date: November 07, 2018
Intervention Type: Biological
Study Phase: Phase 1
View 8 Less Clinical Trials

286 Total Publications

Pancreatic cancer cell-intrinsic transglutaminase-2 promotes T cell suppression through microtubule-dependent secretion of immunosuppressive cytokines.
Pancreatic cancer cell-intrinsic transglutaminase-2 promotes T cell suppression through microtubule-dependent secretion of immunosuppressive cytokines.
Journal: Journal for immunotherapy of cancer
Published: April 18, 2025
Similar Doctors
Distinguished in Hemolytic Anemia
Dr. James R. Eckman
Hematology Oncology
Distinguished in Hemolytic Anemia
Dr. James R. Eckman
Hematology Oncology
80 Jesse Hill Jr Dr Se, 
Atlanta, GA 
 (4.5 miles away)
404-616-4307
Languages Spoken:
English
See accepted insurances

James Eckman is a Hematologist Oncology provider in Atlanta, Georgia. Dr. Eckman is rated as a Distinguished provider by MediFind in the treatment of Hemolytic Anemia. His top areas of expertise are Sickle Cell Disease, Hemoglobinopathy, Congenital Hemolytic Anemia, and Hemolytic Anemia.

Morgan L. Mclemore
Distinguished in Hemolytic Anemia
Dr. Morgan L. Mclemore
Hematology Oncology
Distinguished in Hemolytic Anemia
Dr. Morgan L. Mclemore
Hematology Oncology

Emory Hemophilia Of Georgia

550 Peachtree Street Northeast, MedicalOfficeTower, 
Atlanta, GA 
 (3.6 miles away)
404-778-1900
Experience:
35+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Morgan Mclemore is a Hematologist Oncology provider in Atlanta, Georgia. Dr. Mclemore has been practicing medicine for over 35 years and is rated as a Distinguished provider by MediFind in the treatment of Hemolytic Anemia. His top areas of expertise are Sickle Cell Disease, Hemoglobinopathy, Fanconi Anemia, Bone Marrow Aspiration, and Splenectomy.

Distinguished in Hemolytic Anemia
Dr. Robert C. Brown
Hematology Oncology
Distinguished in Hemolytic Anemia
Dr. Robert C. Brown
Hematology Oncology
5461 Meridian Mark Rd Ste 400, 
Atlanta, GA 
 (7.0 miles away)
404-785-1112
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Robert Brown is a Hematologist Oncology provider in Atlanta, Georgia. Dr. Brown is rated as an Advanced provider by MediFind in the treatment of Hemolytic Anemia. His top areas of expertise are Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, and Hemolytic Anemia. Dr. Brown is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Waller's expertise for a condition
ConditionClose
View All 18 Advanced Conditions
View All 51 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile